Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference
BRISBANE, Calif., Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- Day One Biopharmaceuticals, Inc. ( Nasdaq: DAWN ) ( "Day One" or the "Company" ) , a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today ...
Wall Street Analysts Believe Day One Biopharmaceuticals ( DAWN ) Could Rally 161.36%: Here's is How to Trade
The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 161.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Cidara Therapeutics, Inc. ( Nasdaq - CDTX ) , Mersana Therapeutics, Inc. ( Nasdaq - MRSN ) , TreeHouse Foods Inc. ( NYSE - THS ) , Gulf Island Inc. ( Nasdaq - GIFI )
BALA CYNWYD, Pa., Nov. 14, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
Halper Sadeh LLC Encourages MRSN, THS, HBAN Shareholders to Contact the Firm to Discuss Their Rights - Mersana Therapeutics ( NASDAQ:MRSN ) , Huntington Bancshares ( NASDAQ:HBAN )
NEW YORK, Nov. 14, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Mersana Therapeutics, Inc. ( NASDAQ: MRSN )
NEW YORK, Nov. 13, 2025 ( GLOBE NEWSWIRE ) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC ( the "M&A Class Action Firm" ) , has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.
Dow Dips Over 400 Points; JD.com Posts Upbeat Q3 Results - Applied Therapeutics ( NASDAQ:APLT ) , EPWK Holdings ( NASDAQ:EPWK )
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 400 points on Thursday. The Dow traded down 0.92% to 47,811.37 while the NASDAQ fell 1.89% to 22,964.17. The S&P 500 also fell, dropping, 1.20% to 6,769.03. Health care shares jumped by 1% on Thursday.
Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout - Mersana Therapeutics ( NASDAQ:MRSN ) , Day One Biopharmaceutical ( NASDAQ:DAWN )
Day One Biopharmaceuticals ( NASDAQ:DAWN ) on Thursday agreed to acquire Mersana Therapeutics Inc. ( NASDAQ:MRSN ) , a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates ( ADCs ) targeting cancers.
Nasdaq Down Over 150 Points; Disney Shares Fall After Q4 Results - Applied Therapeutics ( NASDAQ:APLT ) , Clearmind Medicine ( NASDAQ:CMND )
U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 150 points on Thursday. Following the market opening Thursday, the Dow traded down 0.08% to 48,216.64 while the NASDAQ fell 0.75% to 23,231.95. The S&P 500 also fell, dropping, 0.40% to 6,823.53.
Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases
Acquisition expands Day One's portfolio with novel antibody-drug conjugate ( ADC ...
Day One Biopharmaceuticals to Acquire Mersana Therapeutics
Agreement with Day One Biopharmaceuticals provides for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to an aggregate of $30.25 per share, for aggregate deal value of up to approximately $285 million ...
Day One Biopharmaceuticals to Acquire Mersana Therapeutics - Mersana Therapeutics ( NASDAQ:MRSN )
Agreement with Day One Biopharmaceuticals provides for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to an aggregate of $30.25 per share, for aggregate deal value of up to approximately $285 million
Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases - Day One Biopharmaceutical ( NASDAQ:DAWN )
Acquisition expands Day One's portfolio with novel antibody-drug conjugate ( ADC ) emiltatug ledadotin ( Emi-Le ) Emi-Le has demonstrated early anti-tumor activity in an ongoing Phase 1 study for adenoid cystic carcinoma type-1 ( ACC-1 ) , a cancer with high unmet need and a lack of ...
Day One Biopharmaceuticals, Inc. ( DAWN ) Reports Q3 Loss, Tops Revenue Estimates
Day One Biopharmaceuticals (DAWN) delivered earnings and revenue surprises of +32.14% and +5.75%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts See a 234.66% Upside in Day One Biopharmaceuticals ( DAWN ) : Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 234.7% in Day One Biopharmaceuticals (DAWN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in ...
Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025
BRISBANE, Calif., Oct. 21, 2025 ( GLOBE NEWSWIRE ) -- Day One Biopharmaceuticals ( Nasdaq: DAWN ) ( "Day One" or the "Company" ) , a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it ...
Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025 - Day One Biopharmaceutical ( NASDAQ:DAWN )
BRISBANE, Calif., Oct. 21, 2025 ( GLOBE NEWSWIRE ) -- Day One Biopharmaceuticals ( NASDAQ:DAWN ) ( "Day One" or the "Company" ) , a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it ...
Wall Street Analysts Think Day One Biopharmaceuticals ( DAWN ) Could Surge 241.59%: Read This Before Placing a Bet
The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 241.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Day One Biopharmaceuticals ( DAWN ) Moves 7.0% Higher: Will This Strength Last?
Day One Biopharmaceuticals (DAWN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Monte Rosa Therapeutics ( GLUE ) Soars 44.1%: Is Further Upside Left in the Stock?
Monte Rosa Therapeutics (GLUE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
XOMA Revenue Jumps 39% in Fiscal Q2
XOMA ( NASDAQ:XOMA ) , a biotechnology royalty aggregator, reported second quarter results on August 13, 2025, for the period ending June 30. The company's revenue ( GAAP ) reached $13.1 million for Q2 2025, surpassing analyst GAAP estimates of $9.39 million.
XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
Business development: Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Royalty's recently announced acquisition of LAVA Therapeutics.
Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Day One Biopharmaceutical ( NASDAQ:DAWN ) , Digital Turbine ( NASDAQ:APPS )
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Wednesday. Shares of Super Micro Computer, Inc. SMCI fell sharply in pre-market trading after the company reported worse-than-expected fourth-quarter financial results and cut its FY26 sales guidance.
Why Astera Labs Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket - Astera Labs ( NASDAQ:ALAB ) , Digital Turbine ( NASDAQ:APPS )
Shares of Astera Labs, Inc. ALAB rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results and issued third-quarter guidance above estimates. The company reported a 20% quarter-over-quarter increase in revenue, reaching a record $191.9 ...
Day One ( DAWN ) Q2 Revenue Jumps 313%
Day One Biopharmaceuticals ( NASDAQ:DAWN ) , a clinical-stage biopharmaceutical company focused on developing therapies for pediatric cancers and rare tumor types, reported its earnings for Q2 2025 on August 5, 2025. The main headline: robust growth in OJEMDA ( tovorafenib ) prescription numbers ...
Wall Street Analysts Believe Day One Biopharmaceuticals ( DAWN ) Could Rally 303.46%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 303.5% in Day One Biopharmaceuticals (DAWN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in ...
Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025
BRISBANE, Calif., July 22, 2025 ( GLOBE NEWSWIRE ) -- Day One Biopharmaceuticals ( Nasdaq: DAWN ) ( "Day One" or the "Company" ) , a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it ...
Day One Biopharmaceuticals, Inc. ( DAWN ) Reports Q1 Loss, Tops Revenue Estimates
Day One Biopharmaceuticals (DAWN) delivered earnings and revenue surprises of 23.91% and 4.90%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Siren Biotechnology Expands Clinical and Scientific Advisory Board with Key Industry Leaders
SAN FRANCISCO, March 05, 2025 ( GLOBE NEWSWIRE ) -- Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for Cancer, today announced the appointment of three distinguished industry and academic experts to its Clinical and Scientific Advisory Board.
Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations
Jazz reports better-than-expected fourth-quarter results. Its newly issued EPS guidance of $22.50-$24.00 for full-year 2025 surpasses our expectations.
Day One Biopharmaceuticals, Inc. ( DAWN ) Reports Q4 Loss, Tops Revenue Estimates
Day One Biopharmaceuticals (DAWN) delivered earnings and revenue surprises of -97.14% and 7.74%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Perrigo Gears Up to Report Q4 Earnings: Here's What to Expect
PRGO's fourth-quarter top line is likely to have benefited from higher net price realization for its products through strategic price increases.
Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates
INSM posts wider-than-expected Q4 loss. It reiterates its 2025 sales outlook for Arikayce in the range of $405-$425 million.
BioMarin Q4 Earnings & Sales Top Estimates, Stock Up on Upbeat '25 View
BMRN reports better-than-expected fourth-quarter results, driven by encouraging uptake for Voxzogo. It reiterates its guidance of generating $4 billion in total sales by 2027.
Does Day One Biopharmaceuticals ( DAWN ) Have the Potential to Rally 193.16% as Wall Street Analysts Expect?
The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 193.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
New Strong Buy Stocks for February 13th
SYF, SSB, VCYT, DAWN and FISI have been added to the Zacks Rank #1 (Strong Buy) List on February 13, 2025.
The Pediatric Brain Tumor Foundation welcomes Day One Biopharmaceuticals' renowned Dr. Samuel C. Blackman to its Board of Directors
BOSTON, Jan. 30, 2025 ( GLOBE NEWSWIRE ) -- The Pediatric Brain Tumor Foundation ( PBTF ) is proud to welcome Dr. Samuel Blackman, MD, PhD to the PBTF's Board of Directors.
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025
Here we present three biotech stocks, ALLO, DAWN and IMCR, which took a beating in 2024 but have upside potential for 2025.
Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Day One Biopharmaceutical ( NASDAQ:DAWN )
BRISBANE, Calif., Dec. 17, 2024 ( GLOBE NEWSWIRE ) -- Day One Biopharmaceuticals DAWN ( "Day One" or the "Company" ) , a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy ...
Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Dec. 17, 2024 ( GLOBE NEWSWIRE ) -- Day One Biopharmaceuticals ( Nasdaq: DAWN ) ( "Day One" or the "Company" ) , a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced ...
Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
Dr. Blackman's departure planned for end of ...
Wall Street Analysts See a 136.83% Upside in Day One Biopharmaceuticals ( DAWN ) : Can the Stock Really Move This High?
The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 136.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Carvana ( NYSE:CVNA )
Shares of Carvana Co. CVNA rose in today's pre-market trading after the company reported better-than-expected third-quarter financial results. Carvana reported third-quarter revenue of $3.66 billion, beating the consensus estimate of $3.45 billion, according to Benzinga Pro.
Day One Biopharmaceuticals, Inc. ( DAWN ) Surpasses Q3 Earnings and Revenue Estimates
Day One Biopharmaceuticals (DAWN) delivered earnings and revenue surprises of 290% and 144.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Day One Reports Third Quarter 2024 Financial Results and Corporate Progress
Achieved $20.1 million in OJEMDATM ( tovorafenib ) net product revenue ...
Wall Street Analysts Think Day One Biopharmaceuticals ( DAWN ) Could Surge 140.71%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 140.7% in Day One Biopharmaceuticals (DAWN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in ...
Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- Reported combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma ( PTCL ) cohort of the Phase 2 NAVAL-1 trial demonstrating Nana-val's substantial antitumor activity and generally well-tolerated safety profile -
Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- Reported combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma ( PTCL ) cohort of the Phase 2 NAVAL-1 trial demonstrating Nana-val's substantial antitumor activity and generally well-tolerated safety profile ...
Engrail Therapeutics Appoints Paul Cayer as Chief Financial Officer and Saira Ramasastry to Board of Directors
SAN DIEGO, Aug. 08, 2024 ( GLOBE NEWSWIRE ) -- Engrail Therapeutics, a precision neuroscience company focused on the development of transformational therapies to improve the lives of patients, today announced the appointment of Paul Cayer as chief financial officer, and Saira Ramasastry to the ...
Meta To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Thursday - Meta Platforms ( NASDAQ:META )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Morgan Stanley raised the price target for Zeta Global Holdings Corp. ZETA from $18 to $30.
Day One Biopharmaceuticals, Inc. ( DAWN ) Reports Q2 Loss, Tops Revenue Estimates
Day One Biopharmaceuticals (DAWN) delivered earnings and revenue surprises of 92.54% and 810.22%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
